06/09/2026
A cannabis compound may have just given cancer researchers a very interesting new lead. 🌿🔬
A newly published study has found that brief, low-dose modulation of the cannabinoid receptor CB2R can change the behaviour of breast cancer cells in ways that appear to make them less aggressive and less adaptable.
The researchers found that a short treatment could:
• Reduce cancer cell self-renewal
• Reduce invasiveness
• Reduce tumour-initiating capacity
• Stabilise cells into a more mature, luminal-like state
• Increase sensitivity to the breast cancer drug tamoxifen
• Limit the emergence of resistant cancer-cell states
And here’s where it gets particularly interesting…
The effects persisted after the treatment was removed.
Rather than simply killing cancer cells, the research suggests that temporarily influencing the CB2 cannabinoid receptor may alter the identity and behaviour of cancer cells — potentially making them less capable of adapting and becoming more aggressive.
The researchers describe this as a potential differentiation-based approach to restricting breast cancer cell plasticity.
Importantly, this is still preclinical research. The study used laboratory models, patient-derived tumour organoids and in vivo preclinical models to investigate these effects. Further preclinical trials and, ultimately, properly designed clinical trials in patients will be needed to determine whether these findings can translate into an effective treatment.
So this provides another fascinating insight into how the endocannabinoid system — and particularly CB2R — may influence cancer cell behaviour.
Four days of treatment. Potentially much longer-lasting cellular changes.
That’s the part of this research that really deserves attention. 👀🌿
SOURCE:
Martínez-Illescas et al., “Transient CB2R modulation durably restricts breast cancer plasticity by stabilizing a luminal-like cell identity,” Communications Biology, 2026.
